INCOG BioPharma将投资200M美元,以扩大其印地安那设施,创造1 000个就业机会,并在2030年之前促进全球无菌注射剂的生产。 INCOG BioPharma will invest $200M to expand its Indiana facility, creating 1,000 jobs and boosting global production of sterile injectables by 2030.

INCOG 生物药剂处将从2026年开始投资2亿美元,扩大其渔业公司印第安纳的设施,增加30万平方英尺,以促进不育注射用生物药剂的生产。 INCOG BioPharma Services will expand its Fishers, Indiana, facility with a $200 million investment starting in 2026, adding 300,000 square feet to boost production of sterile injectable biopharmaceuticals. 预计到2030年,该升级站将每年生产多达4.8亿个单位,将作为一个全球制造枢纽,创造大约1 000个就业机会,并提高填充/加工、自动化和装置装配能力。 The upgraded site, expected to produce up to 480 million units annually by 2030, will serve as a global manufacturing hub, creating around 1,000 jobs and enhancing capabilities in fill/finish, automation, and device assembly. 该项目反映了对长效注射药物需求的增加,并加强了INCOG在全世界供应高价值注射药物方面的作用。 The project reflects rising demand for long-acting injectables and strengthens INCOG’s role in supplying high-value injectable drugs worldwide.